Pioneer in phage-based diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations
Menu
  • Home
  • About
    • About PBD Biotech
    • Leadership
    • Blog
  • Latest
    • Press releases
    • In the news
    • Events
  • Actiphage TB
    • What is Actiphage TB?
    • Unique role in TB testing
    • Supporting test and treat campaigns
    • Clinical studies
  • Lab Support
    • Laboratory Support
    • Solutions for laboratory developed tests
    • Actiphage assay workflow
    • Instructions for use of Actiphage
  • TB Drug Research
    • TB drug research
    • Research Use Only
    • Biomarker for TB prevention
  • Contact
    • Contacting us
    • Partnerships and collaborations

Promising TB diagnostic Actiphage selected for evaluation by R2D2 TB Network

Ease of use at the point of need is vital for the roll out of a diagnostic, so PBD Biotech, developers of Actiphage - a rapid blood test for early-stage tuberculosis - is partnering with the Rapid Research in Diagnostics Development for TB Network (R2D2 TB Network) funded by the US National Institutes of Health to gain a lab side evaluation of its diagnostic at a clinical site in the Philippines.
  • September 30, 2022
  • Human health, Press release
  • human TB, R2D2 TB Network, TB diagnostic
Rapid Research in Diagnostics Development for TB Network R2D2 TB Network
R2D2 TB Network in the Philippines is to gain a lab side evaluation of Actiphage

TB is treatable, but every year 3 million people remain undiagnosed and 1 million die. So, a rapid way to screen vulnerable populations to detect those at most risk of developing the disease would have a massive impact on the quality of life and economic prospects of these communities.

PBD Biotech’s Actiphage® blood test is sensitive and specific, and clinical trials by Leicester Tuberculosis Research Group (LTBRG) have shown that it is able to diagnose human TB at a very early stage, before the patient shows clinical symptoms.

Further clinical trials are underway to test its effectiveness in the field, but in parallel with this, the analytical process needs to be robust and easy to replicate in a clinical laboratory.

R2D2 TB Network supports promising TB diagnostics

To accelerate the development of effective screening tests, the R2D2 TB Network provides a transparent process for identification and advancement of the most promising TB diagnostics. It brings together leading international experts in TB diagnostics research, registration pathways and policy development and has clinical study sites in six countries. It is funded by the US National Institute of Health and National Institute of Allergy and Infectious diseases.

R2D2 will be assessing how easy it is for lab technicians to perform the analysis and the type and level of support that might be required.

Value the independent evaluation

Jane Theaker, CEO of PBD Biotech says: “The R2D2 TB Network is very highly regarded, and we greatly value its support in evaluating the analytical process at its clinical facilities in the Philippines. This end-user feedback will be invaluable in further developing Actiphage, so it is easy to use with minimal training.”

Adithya Cattamanchi, one of the principal investigators involved with R2D2 TB Network comments: “Connecting developers to the communities in which the diagnostics are to be used is a vital part of our work and we are delighted to working with PBD Biotech on this promising diagnostic.”

The R2D2 TB Network has an extensive network of clinical trial sites, which includes:
Asia (India, Vietnam, the Philippines), Africa (Uganda, South Africa), and Eastern Europe (Georgia) with extensive TB and respiratory disease expertise.

More about R2D2 TB Network

Share:

Related posts

Loading...
AACC webinar phage-based TB diagnostics

PBD Biotech announces AACC webinar to support awareness of new TB diagnostics

March 23, 2023
We embrace the World TB day theme 'Yes! We Can End TB' with an educational webinar event on new diagnostic tests that are urgently needed to screen LTBI and determine who will progress to active TB disease.
AACC webinar phage-based TB diagnostics

PBD Biotech announces AACC webinar to support awareness of new TB diagnostics

March 23, 2023
We embrace the World TB day theme 'Yes! We Can End TB' with an educational webinar event on new diagnostic...
Marie Roskrow

TB blood-test developers PBD Biotech appoint Dr Marie Roskrow as Chair

January 17, 2023
Identifying those most at risk of active TB disease becomes a priority as fatalities increase. In response to this need, PBD Biotech is announcing that it has appointed Dr Marie Roskrow to chair its board and has expanded its scientific...
Marie Roskrow

TB blood-test developers PBD Biotech appoint Dr Marie Roskrow as Chair

January 17, 2023
Identifying those most at risk of active TB disease becomes a priority as fatalities increase. In response to this need,...
Pictured from left are Ray Harris from Foresight, Sandy Reid of Mercia Asset Management, Jane Theaker of PBD Biotech and Mark Wilcockson of British Business Bank

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test

October 17, 2022
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic with potential to revolutionise management of TB.
Pictured from left are Ray Harris from Foresight, Sandy Reid of Mercia Asset Management, Jane Theaker of PBD Biotech and Mark Wilcockson of British Business Bank

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test

October 17, 2022
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic...
ECCMID

Actiphage TB diagnostic finds live mycobacterium tuberculosis in the blood of people with incipient TB

April 23, 2022
A clinical trial of Actiphage, a promising new diagnostic for tuberculosis infection, has shown for the first time that live bacteria can be detected in the blood of people with incipient TB infection.
ECCMID

Actiphage TB diagnostic finds live mycobacterium tuberculosis in the blood of people with incipient TB

April 23, 2022
A clinical trial of Actiphage, a promising new diagnostic for tuberculosis infection, has shown for the first time that live...
1 2 Next »

developers of phage-based diagnostics

Contact Us
BIVDA member 2023

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!